Daval International Limited Gains Approval for Phase IIB Trial of AIMSPRO(R)

Daval International Limited, a UK private company, announces MHRA and IRB (Ethics Committee) approval of a London based Phase IIB trial of AIMSPRO(R), its hyperimmune caprine serum derivative.

This double-blind placebo-controlled cross-over study will seek to detect a beneficial effect on bladder function in patients with Secondary Progressive Multiple Sclerosis, following open-label observations over several years in a number of informed consent, "compassionate basis" patients.

AIMSPRO has an "export only" listing on the Australian Registry of Therapeutic Goods and a TGA Orphan Status Designation for the treatment of Krabbe's disease. An IND application is being lodged for a further MS trial in

the United States.

AIMSPRO is a frozen medication, given as a 1ml sub-cutaneous injection every 4 days. It is believed to have a pronounced and sustained anti-inflammatory action with an associated, novel effect of lowering sodium channel triggering voltages in nerve fibres. MHRA applications for two further clinical trials are to be lodged within the next 3 months.

Daval International Ltd. has recently been accepted as a member of the Association of the British Pharmaceutical Industry. "ABE"

Daval International Limited

Daval International Limited is a privately owned British pharmaceutical company, which, since 2001, has been developing an immunologically active human and veterinary medication derived from goat serum. Some 20.000 doses of Aimspro have been administered, mainly to human subjects with multiple sclerosis, with an excellent safety and tolerance profile.

SOURCE: Daval International Ltd

CONTACT: Dr. Bryan Youl,

+44(0)7793-526-096, or

Brian Quick,

+44(0)7764-828-114,

both of Daval International Ltd,

[email protected]

--Distributed by AsiaNet ( www.asianetnews.net )--

Merck to Showcase New Data at ACTRIMS-ECTRIMS MSVirtual2020 Meeting, Furthering Innovation in Multiple Sclerosis

Not intended for UK and US based media - Company to present 54 abstracts across its MS portfolio MAVENCLAD(R) (cladribine tablets), Rebif(R) (interferon beta-1a) and investigational evobrutinib - New long-term data and real-world evidence further characterise efficacy and safety of MAVENCLAD(R) - New MAVENCLAD(R) and Rebif(R) safety data to be shared demonstrating no increased risk of respiratory viral infections Merck, a leading science and technology company, today announced it will present

03 กันยายน 2563 19:00 น.

Merck and Twitch Join Forces on World Multiple Sclerosis Day to Connect People Living With MS

- Merck and Twitch collaborate on World MS Day to increase understanding of the impact of multiple sclerosis (MS) - Livestream event with Twitch influencers on May 30 will raise awareness and money for the... พ.ค. 63

Global Survey and Documentary Film Expose Emotional Impact of Multiple Sclerosis

Not intended for U.S media - Merck-sponsored survey developed in collaboration with IACO and Eurocarers reveals lifelong effects of caring for a loved one with MS - #MSInsideOut documentary film, executively produced by... ต.ค. 61

รพ. กรุงเทพ ชี้ “3M โรคความเสื่อมทางสมอง ที่ต้องใส่ใจให้รู้เท่าทัน!” เพื่อป้องกันและหาแนวทางการรักษาได้อย่างตรงจุด — แก่แบบมีคุณภาพ นอกจากจะมีคุณภาพชีวิตท... พ.ค. 60

งาน See the light of the Brain รู้เท่าทันโรคสมอง 3M (Memory, Moving, Multiple Sclerosis) — เสาร์ที่ 27 พฤษภาคม 2560 เวลา 08.00-12.00 น. ศูนย์สมองและระบบปร... พ.ค. 60

ภาพข่าว: PACTRIMS ครั้งที่ 9 เพื่อคุณภาพชีวิตที่ดีขึ้นของผู้ป่วยโรคเอ็มเอส — เมื่อเร็วๆนี้ ศ.พญ.สุวรรณา เรืองกาญจนเศรษฐ์ (กลาง) ประธานชมรมเอ็มเอสไทย พร้อม... พ.ย. 59

S1P1 Agonists are Currently Indicated For Treatment of Multiple Sclerosis

S1P1 LEAD COMPOUNDS, AMG 369 AND AMG 277, WILL BE OFFERED FOR SALE AT A DECEMBER 8, 2011 SEALED BID SALE Joseph F. Finn, Jr., C.P.A. ("Finn") Assignee for the Benefit of Creditors of Epix Pharmaceuticals, Inc. ("Epix")... ต.ค. 54

Investigational Oral Multiple Sclerosis Therapy Teriflunomide (*) Aubagio (R)) Significantly Reduced Relapse Rate, Disability Progression and Disease Activity

- Findings from Two-Year Pivotal Phase III TEMSO Trial Published today in The New England Journal of Medicine - Sanofi (EURONEXT: SAN and NYSE... ต.ค. 54

Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients

- Phase III TEMSO Study Meets Goals Including Delayed Disability Progression for Teriflunomide 14mg Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today the results from the two year phase III... ต.ค. 53

Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO-01 Trial in Secondary Progressive Multiple Sclerosis

Eli Lilly and Company (NYSE: LLY) and BioMS Medical Corp. (TSX: MS) today announced that dirucotide did not meet the primary endpoint of delaying disease progression, as measured by the... ก.ค. 52